Neurolixis Announces Publications Demonstrating Effects of NLX-112 in Parkinson


(February 25, 2016) - Neurolixis, Inc. announced the recent publication of two scientific articles demonstrating robust effects of the Company’s lead drug candidate, NLX-112, in rodent models of Parkinson’s disease. As described in these publications, NLX-112, a selective serotonin 5-HT1A receptor agonist, exhibited potent activity in parkinsonian rats, producing an immediate and complete abolition of L-DOPA-induced dyskinesia (LID). Read more

Click for a printer friendly version

Back to top